Dipeptidyl peptidase IV (DPP-IV) is a key therapeutic target for T2D, as it deactivates the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which regulate postprandial insulin secretion and blood glucose levels. This evidence concerns the gene GIP and type 2 diabetes mellitus.